NFKB1 and COVID-19: Activation of the NF-κB (nuclear factor kappa B) signaling pathway was also shown to contribute to the inflammation induced after SARS-CoV-1 infection [31]; therefore, NF-κB inhibitors may be promising for the treatment of severe COVID-19.